Avi Nandi
About Avi Nandi
Title: Chief Technical Officer
Avi Nandi holds the position of Chief Technical Officer. In this capacity, Nandi oversees the technical direction and overall strategy for the company. With extensive experience in gene therapy, viral vectors, and vaccine development, he ensures that the technological developments align with the organization's goals and regulatory requirements.
Education and Expertise in Biology
Avi Nandi holds a Master's degree in Biology and completed an MBA in October 2021. His expertise spans gene therapy, viral vectors, and vaccine development, underpinned by academic qualifications and significant professional experience. Nandi's background in biology provides the technical foundation for his work in various high-impact roles across the biotechnology industry.
Industry Background and Career History
Avi Nandi's career includes pivotal roles in several renowned organizations. He served as the Global Head of Technical Development at AveXis / Novartis Gene Therapies. Prior to this, he was the Head of Virology and Cell Culture, Process and Product Development Lead at Seqirus / CSL, and worked as a Technical Development Scientist at Novartis Vaccines and Diagnostics. Nandi also conducted research as a Viral Pathogenesis Scientist at Harvard Medical School, showcasing a robust trajectory in viral and gene therapy domains.
Achievements in Gene Therapy and Viral Vector Development
Avi Nandi has played a crucial role in the regulatory approval of ZOLGENSMA in the US and over 10 other markets. He has supported a pipeline of over 15 gene therapy products from preclinical to Phase III development. Nandi's contributions also include leading the development and implementation of four gene therapy manufacturing processes across four GMP and three laboratory sites, reflecting his deep involvement in advancing medical treatments.
Experience in Vaccine and Viral Vector Technologies
With over 10 years of experience in vaccine and viral vector development, Avi Nandi has worked with multiple virus platforms including AAV, adenovirus, herpesvirus, alphavirus, lentivirus, and RNA. His extensive background in these technologies enables him to innovate and guide significant advancements in vaccine and gene therapy fields, ensuring the development of effective and safe medical products.